Alpha vs beta emitters
Beta particles (lutetium-177) travel millimetres and are good for bulky disease; alpha particles (actinium-225) travel a few cells' width and kill with far higher energy.
Overview
This is about alpha particles versus beta particles in radioligand therapy, not the alpha/beta ratio of the linear-quadratic model used in external-beam fractionation. Beta and alpha emitters are the two kinds of particle used in radioligand therapy. Beta particles from lutetium-177 have low linear energy transfer and a range of 1 to 10 mm, so their crossfire helps in heterogeneous bulky tumours at the cost of marrow toxicity. Alpha particles from actinium-225 have very high linear energy transfer, around 100 keV per micrometre, travel only 50 to 100 micrometres and cause oxygen-independent DNA breaks, though daughter recoil redistributes dose and actinium-225 supply is the bottleneck. The distinction underlies the Radioligand therapy (beta emitters) and Targeted alpha therapy technologies and the pairing Beta radioligand to alpha radioligand, and it is referenced by Radium-223 dichloride and the Neuroendocrine tumours entry.
- PSMA / SSTR-positive cell
Showing the technology this term belongs to: Radioligand therapy (beta emitters).
Similar pages
not linked directly; found by shared links- TermDosimetry
Shares Regional cyclotron hubs for actinium-225 with an agreed actinium-227 impurity limit, Half-life, Alpha-emitter nanogenerators and daughter trapping, Wrong doses.
- Key paperRadiopharmaceutical therapy in cancer: clinical advances and challenges
Shares Radium-223, Targeted alpha therapy, Actinium-225, Radioligand therapy (beta emitters).
- TrialACTION-1
Shares Beta PRRT → alpha PRRT, Targeted alpha therapy, Neuroendocrine tumours, Actinium-225.
- RoadmapRadiopharmaceutical roadmap: iodine → lutetium → actinium
Shares Beta radioligand → alpha radioligand, Radium-223, Manufacturing cost and time for living and radioactive medicines, Targeted alpha therapy.
- RoadmapAlpha-emitter roadmap: radium-223 → 225Ac-PSMA-617 → a phase 3 pipeline
Shares Alpha-emitting PSMA therapy at first metastatic diagnosis, Radium-223 dichloride, Radium-223, Targeted alpha therapy.
- CompanyBayer
Shares Oslo University Hospital, The Norwegian Radium Hospital, Radium-223 dichloride, Radium-223, Actinium-225.
- BottleneckActinium-225 supply
Shares Regional cyclotron hubs for actinium-225 with an agreed actinium-227 impurity limit, Fund alpha emitters beyond actinium-225: lead-212, terbium-149 and astatine-211, Manufacturing cost and time for living and radioactive medicines, Targeted alpha therapy.
- IdeaA global medical isotope supply observatory with forecasts and shortage alerts
Shares Manufacturing cost and time for living and radioactive medicines, Targeted alpha therapy, Actinium-225, Radioligand therapy (beta emitters).